GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anebulo Pharmaceuticals Inc (NAS:ANEB) » Definitions » Price-to-Owner-Earnings

Anebulo Pharmaceuticals (Anebulo Pharmaceuticals) Price-to-Owner-Earnings : (As of May. 18, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Anebulo Pharmaceuticals Price-to-Owner-Earnings?

As of today (2024-05-18), Anebulo Pharmaceuticals's share price is $2.2999. Anebulo Pharmaceuticals does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Anebulo Pharmaceuticals's Price-to-Owner-Earnings or its related term are showing as below:


ANEB's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 35.58
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-18), Anebulo Pharmaceuticals's share price is $2.2999. Anebulo Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.37. Therefore, Anebulo Pharmaceuticals's PE Ratio for today is At Loss.

As of today (2024-05-18), Anebulo Pharmaceuticals's share price is $2.2999. Anebulo Pharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.37. Therefore, Anebulo Pharmaceuticals's PE Ratio without NRI for today is At Loss.


Anebulo Pharmaceuticals Price-to-Owner-Earnings Historical Data

The historical data trend for Anebulo Pharmaceuticals's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anebulo Pharmaceuticals Price-to-Owner-Earnings Chart

Anebulo Pharmaceuticals Annual Data
Trend Jun20 Jun21 Jun22 Jun23
Price-to-Owner-Earnings
- - - -

Anebulo Pharmaceuticals Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Anebulo Pharmaceuticals's Price-to-Owner-Earnings

For the Biotechnology subindustry, Anebulo Pharmaceuticals's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anebulo Pharmaceuticals's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anebulo Pharmaceuticals's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Anebulo Pharmaceuticals's Price-to-Owner-Earnings falls into.



Anebulo Pharmaceuticals Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Anebulo Pharmaceuticals's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=2.2999/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anebulo Pharmaceuticals  (NAS:ANEB) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Anebulo Pharmaceuticals Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Anebulo Pharmaceuticals's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Anebulo Pharmaceuticals (Anebulo Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
1017 Ranch Road 620 South, Suite 107, Lakeway, TX, USA, 78734
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company. It is developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.
Executives
Bimal R. Shah director C/O SPECTRUM PHARMACEUTICALS, 11500 SOUTH EASTER AVENUE, SUITE 240, HENDERSON NV 89052
Richard Anthony Cunningham, director, officer: Chief Executive Officer ONE KENDALL SQUARE, BUILDING 200 SUITE 2, CAMBRIDGE MA 02139
Dan George officer: Chief Financial Officer 1412 62ND STREET, EMERYVILLE CA 94608
Sandra A. Gardiner officer: Acting Chief Financial Officer CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005
Kenneth C Cundy officer: Chief Scientific Officer 1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025
Nathaniel Calloway director C/O ANEBULO PHARMACEUTICALS, INC., 1415 RANCH ROAD 620 SOUTH, SUITE 201, LAKEWAY TX 78734
Simon Allen director, officer: Chief Executive Officer C/O AMBRX, INC., 10975 N. TORREY PINES RD., LA JOLLA CA 92037
Aron R. English director, 10 percent owner 1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107
Kenneth Lin director PO BOX 1005, LOS ALTOS CA 94022
Karah Herdman Parschauer director 60 LEVERONI COURT, NOVATO CA 94949
22nw Fund, Lp 10 percent owner 1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107
Joseph F. Lawler director, 10 percent owner 2110 RANCH ROAD 620 S, #341732, LAKEWAY TX 78734
Areta Kupchyk director C/O ANEBULO PHARMACEUTICALS, INC., 1415 RANCH ROAD 620 SOUTH, SUITE 201, LAKEWAY TX 78734
Jason Aryeh director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
22nw, Lp 10 percent owner, other: See Explanation of Response 590 1ST AVE S, UNIT C1, SEATTLE WA 98104

Anebulo Pharmaceuticals (Anebulo Pharmaceuticals) Headlines

From GuruFocus